Peel Hunt Limited Reiterates Hikma Pharmaceuticals (HKMPF) Buy Recommendation

Peel Hunt Limited reiterated a Buy recommendation for Hikma Pharmaceuticals (HKMPF) on November 7, 2025, setting an average one-year price target of $33.13, which suggests a 31.21% upside from its current $25.25. This positive analyst view comes alongside projected annual revenue of $2,880MM, a 10.45% decrease, and non-GAAP EPS of $2.12. Institutional sentiment indicates increased conviction, with total shares owned by institutions rising 38.93% to 8,508K and the average portfolio weight dedicated to HKMPF increasing by 24.30%, notably driven by a significant 62.34% increase in John Hancock Disciplined Value International Fund's holdings.

Analysis

Peel Hunt reiterated a "Buy" rating for Hikma Pharmaceuticals (HKMPF) on November 7, 2025, setting an average one-year price target of $33.13. This target implies a significant 31.21% upside from the recent closing price of $25.25, reflecting a strong analyst conviction despite some challenging financial projections. The target range spans from $26.54 to $39.88, indicating a broad spectrum of potential outcomes.

Despite this positive analyst outlook, Hikma projects a 10.45% decrease in annual revenue to $2,880MM, alongside a non-GAAP EPS of $2.12. However, institutional ownership data reveals a strong increase in conviction, with total shares owned by institutions rising 38.93% to 8,508K shares over the last three months. The average portfolio weight dedicated to HKMPF also increased by 24.30%, indicating growing institutional interest.

This increased institutional interest is largely driven by specific funds like John Hancock Disciplined Value International Fund, which significantly boosted its HKMPF holdings by 62.34% and its portfolio allocation by 83.23%. Conversely, several Vanguard funds reduced their positions and portfolio allocations, suggesting a divergence in institutional strategies regarding Hikma's future prospects. The overall increase in institutional shares, despite a slight decrease in the number of reporting funds, points to larger allocations by existing or new significant holders.

Key Decisions for Investors

• Consider the strong analyst "Buy" rating and the substantial implied upside of 31.21% to the average price target, balancing it against the projected revenue decline.
• Monitor Hikma's upcoming earnings reports for actual revenue performance and EPS, as the projected decrease is a key risk factor despite positive institutional flows.
• Evaluate the divergence in institutional positioning, particularly the significant increase by John Hancock versus decreases by Vanguard funds, to understand varying investment theses and potential catalysts.